Skip to content

Effects of Cholecystectomy on Pancreatic Exocrine Function and the Underlying Mechanisms

Effects of Cholecystectomy on Pancreatic Exocrine Function and the Underlying Mechanisms

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102559
Enrollment
Unknown
Registered
2025-05-16
Start date
2025-05-18
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exocrine Pancreatic Insufficiency

Interventions

Control group:None

Sponsors

The Second Hospital of Lanzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18–70 years; 2) Having undergone cholecystectomy (laparoscopic or open) with a postoperative period of =6 months; 3) Voluntarily participating and signing the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Individuals with abnormal routine stool examination results; 2) Patients with severe constipation or inability to defecate voluntarily; 3) Pregnant or lactating women; 4) Patients with malignancies, high fever, severe infections, or severe cardiac, cerebral, hepatic, or renal disorders; 5) Individuals with organic gastrointestinal diseases or a history of gastrointestinal surgery; 6) Patients with gastrointestinal bleeding; 7) Cases of gastrointestinal outflow obstruction or mechanical ileus; 8) Patients with conditions affecting digestion/absorption (e.g., inflammatory bowel disease, liver cirrhosis); 9) Individuals with systemic metabolic disorders (e.g., thyroid dysfunction, diabetes mellitus, hyperlipidemia); 10) Patients with a history of acute/chronic pancreatic diseases, pancreatic surgery, or pancreatic trauma; 11) Use of somatostatin, aprotinin, or drugs known to induce/exacerbate pancreatic exocrine insufficiency within the past 2 weeks; 12) Use of medications altering fat absorption (e.g., Orlistat, other weight-loss drugs, ursodeoxycholic acid) within the past 2 weeks.

Design outcomes

Primary

MeasureTime frame
Fecal elastase-1,FE-1;

Secondary

MeasureTime frame
Gastrointestinal quality of life index,GIQLI;Gastrointestinal Symptom Rating Scale,GSRS;

Countries

China

Contacts

Public ContactGuoqing Qi

The Second Hospital of Lanzhou University

q5225@163.com+86 150 0250 3418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026